Non-hodgkin lymphoma of the stomach in a patient treated with natalizumab

Jennie Y. Law; Dong W. Kim; Ariel Sturgis; Harris V. Naina

doi:10.4137/CMO.S27142

Non-hodgkin lymphoma of the stomach in a patient treated with natalizumab

Jennie Y. Law, Dong W. Kim, Ariel Sturgis, Harris V. Naina

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

A 61-year-old man with relapsing-remitting multiple sclerosis developed extranodal large B-cell lymphoma of the stomach following monthly natalizumab infusions for 6 years. Development of lymphoproliferative disorders increases with chronic use of immunosuppression. Cases of primary central nervous system lymphoma as well as one case of peripheral T-cell lymphoma have previously been reported with natalizumab use. Given the absence of a known association between multiple sclerosis and extranodal presentations of diffuse large B-cell lymphoma, a causal association with natalizumab administration cannot be excluded.

Original language	English (US)
Pages (from-to)	61-63
Number of pages	3
Journal	Clinical Medicine Insights: Oncology
Volume	9
DOIs	https://doi.org/10.4137/CMO.S27142
State	Published - 2015

Keywords

Multiple sclerosis
Natalizumab
Non-Hodgkin lymphoma of the stomach

ASJC Scopus subject areas

Oncology

Access to Document

10.4137/CMO.S27142

Cite this

@article{9a49a4e8647f4e18a973d6b270b1249c,

title = "Non-hodgkin lymphoma of the stomach in a patient treated with natalizumab",

abstract = "A 61-year-old man with relapsing-remitting multiple sclerosis developed extranodal large B-cell lymphoma of the stomach following monthly natalizumab infusions for 6 years. Development of lymphoproliferative disorders increases with chronic use of immunosuppression. Cases of primary central nervous system lymphoma as well as one case of peripheral T-cell lymphoma have previously been reported with natalizumab use. Given the absence of a known association between multiple sclerosis and extranodal presentations of diffuse large B-cell lymphoma, a causal association with natalizumab administration cannot be excluded.",

keywords = "Multiple sclerosis, Natalizumab, Non-Hodgkin lymphoma of the stomach",

author = "Law, {Jennie Y.} and Kim, {Dong W.} and Ariel Sturgis and Naina, {Harris V.}",

note = "Publisher Copyright: {\textcopyright} the authors, publisher and licensee Libertas Academica Limited.",

year = "2015",

doi = "10.4137/CMO.S27142",

language = "English (US)",

volume = "9",

pages = "61--63",

journal = "Clinical Medicine Insights: Oncology",

issn = "1179-5549",

publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Non-hodgkin lymphoma of the stomach in a patient treated with natalizumab

AU - Law, Jennie Y.

AU - Kim, Dong W.

AU - Sturgis, Ariel

AU - Naina, Harris V.

N1 - Publisher Copyright: © the authors, publisher and licensee Libertas Academica Limited.

PY - 2015

Y1 - 2015

N2 - A 61-year-old man with relapsing-remitting multiple sclerosis developed extranodal large B-cell lymphoma of the stomach following monthly natalizumab infusions for 6 years. Development of lymphoproliferative disorders increases with chronic use of immunosuppression. Cases of primary central nervous system lymphoma as well as one case of peripheral T-cell lymphoma have previously been reported with natalizumab use. Given the absence of a known association between multiple sclerosis and extranodal presentations of diffuse large B-cell lymphoma, a causal association with natalizumab administration cannot be excluded.

AB - A 61-year-old man with relapsing-remitting multiple sclerosis developed extranodal large B-cell lymphoma of the stomach following monthly natalizumab infusions for 6 years. Development of lymphoproliferative disorders increases with chronic use of immunosuppression. Cases of primary central nervous system lymphoma as well as one case of peripheral T-cell lymphoma have previously been reported with natalizumab use. Given the absence of a known association between multiple sclerosis and extranodal presentations of diffuse large B-cell lymphoma, a causal association with natalizumab administration cannot be excluded.

KW - Multiple sclerosis

KW - Natalizumab

KW - Non-Hodgkin lymphoma of the stomach

UR - http://www.scopus.com/inward/record.url?scp=84939798993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939798993&partnerID=8YFLogxK

U2 - 10.4137/CMO.S27142

DO - 10.4137/CMO.S27142

M3 - Article

C2 - 26157340

AN - SCOPUS:84939798993

SN - 1179-5549

VL - 9

SP - 61

EP - 63

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

ER -

Non-hodgkin lymphoma of the stomach in a patient treated with natalizumab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this